ES2053403T1 - Diagnosis y tratamiento de estados inflamatorios. - Google Patents

Diagnosis y tratamiento de estados inflamatorios.

Info

Publication number
ES2053403T1
ES2053403T1 ES93202324T ES93202324T ES2053403T1 ES 2053403 T1 ES2053403 T1 ES 2053403T1 ES 93202324 T ES93202324 T ES 93202324T ES 93202324 T ES93202324 T ES 93202324T ES 2053403 T1 ES2053403 T1 ES 2053403T1
Authority
ES
Spain
Prior art keywords
diagnosis
treatment
inflammatory states
immunoglobulin
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES93202324T
Other languages
English (en)
Other versions
ES2053403T3 (es
Inventor
Robert H Rubin
William H Strauss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of ES2053403T1 publication Critical patent/ES2053403T1/es
Application granted granted Critical
Publication of ES2053403T3 publication Critical patent/ES2053403T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Chemical Treatment Of Metals (AREA)

Abstract

SE PRESENTA EL USO DE UNA CANTIDAD EFECTIVA PARA EL DIAGNOSTICO DE UNA INMUNOGLOBULINA ETIQUETADA DE MANERA DETECTABLE O DE UN FRAGMENTO DE LA MISMA, EN DONDE LA INMUNOGLOBULINA SE ACUMULA SUSTANCIALMENTE EN EL LUGAR QUE SE ENCUENTRA INFLAMADO, PARA LA PREPARACION DE UN AGENTE A UTILIZAR EN UN METODO PARA DETECTAR EL LUGAR INFLAMADO DE UN INDIVIDUO.
ES93202324T 1986-01-16 1987-01-16 Diagnosis y tratamiento de la inflamacion. Expired - Lifetime ES2053403T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81958586A 1986-01-16 1986-01-16
US819585 1986-01-16

Publications (2)

Publication Number Publication Date
ES2053403T1 true ES2053403T1 (es) 1994-08-01
ES2053403T3 ES2053403T3 (es) 2005-06-01

Family

ID=25228549

Family Applications (2)

Application Number Title Priority Date Filing Date
ES93202324T Expired - Lifetime ES2053403T3 (es) 1986-01-16 1987-01-16 Diagnosis y tratamiento de la inflamacion.
ES87300395T Expired - Lifetime ES2056812T5 (es) 1986-01-16 1987-01-16 Uso de una inmunoglobulina marcada detectablemente o un fragmento de la misma en la fabricacion de un agente para la deteccion de un sitio de inflamacion in vivo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES87300395T Expired - Lifetime ES2056812T5 (es) 1986-01-16 1987-01-16 Uso de una inmunoglobulina marcada detectablemente o un fragmento de la misma en la fabricacion de un agente para la deteccion de un sitio de inflamacion in vivo.

Country Status (9)

Country Link
EP (2) EP0577225B9 (es)
JP (1) JP2515357B2 (es)
AT (2) ATE110572T1 (es)
AU (1) AU597032B2 (es)
CA (1) CA1288688C (es)
DE (3) DE3750434T3 (es)
ES (2) ES2053403T3 (es)
GR (1) GR940300027T1 (es)
WO (1) WO1987004351A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2515357B2 (ja) * 1986-01-16 1996-07-10 ザ・ジェネラル・ホスピタル・コ−ポレ−ション 炎症の診断方法および治療方法
FR2639231A1 (fr) * 1988-11-23 1990-05-25 Merieux Inst Utilisation de fragments fc d'immunoglobulines g humaines, de peptides analogues du fragment fc, ou d'immunoglobulines g humaines dans l'obtention d'un medicament preparatoire a l'administration chez l'homme, dans un but therapeutique ou de diagnostic, d'anticorps monoclonaux
NZ314680A (en) * 1989-05-09 2000-08-25 Ortho Pharma Corp Treating localised infection or inflammation with a therapeutically conjugated chemotactic peptide
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
EP0485664A1 (en) * 1990-11-13 1992-05-20 Mallinckrodt Diagnostica (Holland) B.V. Method of preparing a diagnostic agent for detecting inflammations
ATE175976T1 (de) * 1993-10-22 1999-02-15 Nihon Mediphysics Co Ltd Peptide mit affinität für entzündungen und deren radiomarkierte, diagnostische zusammensetzungen
DE19514088A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat zur Behandlung von Entzünduns-, Infektions- und/oder Hauterkrankungen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2004464B (en) * 1977-06-30 1982-01-13 Cehovic G Method of testing inflammation
US4315906A (en) * 1979-05-21 1982-02-16 New England Nuclear Corporation Cold insoluble globulin, its purification and use
US4472371A (en) * 1979-10-29 1984-09-18 Summa Medical Corporation Radiolabeled antibody to anti-tumor associated antigen and process
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
GB2101407A (en) * 1981-05-14 1983-01-12 Bulpitt And Sons Limited Automatic electric kettle
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4732864A (en) * 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
GR850552B (es) * 1984-03-07 1985-07-05 Du Pont
US4636380A (en) * 1984-04-23 1987-01-13 Wong Dennis W Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
GB8426470D0 (en) * 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
AU597877B2 (en) * 1984-12-26 1990-06-14 Teijin Limited Anti-pseudomonas aeruginosa human monoclonal antibody
JP2515357B2 (ja) * 1986-01-16 1996-07-10 ザ・ジェネラル・ホスピタル・コ−ポレ−ション 炎症の診断方法および治療方法
GB8610202D0 (en) * 1986-04-25 1986-05-29 Technology Licence Co Ltd Monoclonal antibodies
GB8621910D0 (en) * 1986-09-11 1986-10-15 Technology Licence Co Ltd Monoclonal antibodies

Also Published As

Publication number Publication date
AU597032B2 (en) 1990-05-24
ATE110572T1 (de) 1994-09-15
DE3752380D1 (de) 2005-01-05
EP0241106A2 (en) 1987-10-14
CA1288688C (en) 1991-09-10
DE3752380T2 (de) 2005-11-03
DE3750434T3 (de) 1999-04-08
EP0241106B2 (en) 1998-07-08
ES2056812T3 (es) 1994-10-16
DE3750434D1 (de) 1994-10-06
EP0241106B1 (en) 1994-08-31
EP0577225B9 (en) 2005-03-02
JP2515357B2 (ja) 1996-07-10
DE577225T1 (de) 1994-09-22
AU6937787A (en) 1987-08-14
WO1987004351A1 (en) 1987-07-30
EP0577225A1 (en) 1994-01-05
ATE283710T1 (de) 2004-12-15
GR940300027T1 (en) 1994-05-31
EP0577225B1 (en) 2004-12-01
EP0241106A3 (en) 1989-02-08
ES2056812T5 (es) 1998-11-16
DE3750434T2 (de) 1995-03-23
ES2053403T3 (es) 2005-06-01
JPS63502280A (ja) 1988-09-01

Similar Documents

Publication Publication Date Title
FI883305A7 (fi) Menetelmä ja laite kaasuvuodon ilmaisemiseksi.
ES2087087T3 (es) Metodo rapido para determinar la eficacia de un ciclo de esterilizacion e indicador biologico de lectura rapida.
IT8519102A0 (it) Composizione di organopolisilossano polimerizzabile in un elastomero e relativo impiego.
FI800702A7 (fi) Menetelmä ja laite veriplasman keräämiseksi.
IT1079695B (it) Reattivo di elevata specificita' e sensibilita' per la determinazione quantitativa di composti in tracce in mezzi di vario genere
IT1099451B (it) Procedimento e reagente per la determinazione della alfa-amilasi
ES475984A1 (es) Un metodo para determinar un material inmunologicamente ac- tivo en una muestra.
ES497544A0 (es) Un metodo para detectar sangre oculta en un especimen huma- no.
ES515307A0 (es) Un metodo enzimatico mejorado para el analisis cinetico de fluidos biologicos.
ES516987A0 (es) Un procedimiento para la determinacion cuantitativa del factor xii de coagulacion de la sangre en el plasma sanguineo humano.
ES2054667T3 (es) Anticuerpos monoclonales contra c5a y des-arg74-c5a, su produccion y uso.
ES2030824T3 (es) Dispositivos de ensayos para determinar la sangre oculta y la glucosa.
ES2053403T1 (es) Diagnosis y tratamiento de estados inflamatorios.
ES462069A1 (es) Procedimiento para el enriquecimiento de proteina de teji- dos.
NO870694L (no) Fremgangsmaate for bestemmelse av mikrobekonsentrasjoner med en smelteagarmetode, samt deri anvendte skaaler.
DE68927718D1 (de) Inhibitoren für glykosaminosyl-transferase-v
FI861269A7 (fi) Menetelmä ja testauslaite analyyttien määrittämiseksi.
FI874521A7 (fi) Menetelmä ja laite maanalaisen kulkutien profiilin selvittämiseksi.
FI883778A7 (fi) Tyyppiä III olevan prokollageenin propeptidin vasta-aine ja määritysenetelmä, jossa sitä käytetään.
DE3853898D1 (de) Behandlung der RNase L-Defizienz mit ds RNS.
DK211686A (da) Absorptions-, turbidimetri-, fluorescens- og nefelometrifotometer
ES2117067T3 (es) Procedimiento para la determinacion inmunoquimica de un analito.
NO148894C (no) Slepeplate beregnet for bruk i forbindelse med en oljelense eller lignende.
AR220329A1 (es) Composicion de ensayo para determinar la presencia de sangre o peroxidasa en una muestra de ensayo,dispositivo que la comprende y procedimiento para preparar el dispositivo
IT1209237B (it) Reagente per la determinazione della lipasi e suo impiego.